


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b))

Docket No.
15526 (PC23188A)

In Re Application Of: Sing Rong, et al,



Serial No.

10/696,935

Filing Date

October 30, 2003

Examiner

Unassigned

Group Art Unit

1653

Title: **METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING COMPANION ANIMAL CANCER**

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);


OR

the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.98)

Docket No.
15526 (PC23188A)

In Re Application: **Sing Rong, et al.**



Serial No.

10/696,935

Filing Date

October 30, 2003

Examiner

Unassigned

Group Art Unit

1653

**METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING COMPANION ANIMAL
CANCER**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of _____ is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- Charge the amount of _____
- Credit any overpayment.
- Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on April 26, 2004 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Peter I. Bernstein
Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: **April 26, 2004**

Peter I. Bernstein

Registration No. 43,497

Scully, Scott, Murphy & Presser

400 Garden City Plaza

Garden City, NY 11530

(516) 742-4343

CC:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Sing Rong, et al. Examiner: Unassigned
Serial No.: 10/696,935 Art Unit: 1653
Filed: October 30, 2003 Docket: 15526 (PC23188A)
For: METHODS AND COMPOSITIONS Dated: April 26, 2004
FOR DIAGNOSING AND TREATING
COMPANION ANIMAL CANCER Confirmation No.: 3803

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. S.R. Wiley, et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis", Immunity, Vol. 3, pp. 673-682, (1995);
2. M. Jo, et al., "Apoptosis Induced in Normal Human Hepatocytes by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand", Nature Medicine, Vol. 6, No. 5, pp. 564-567, (2000);

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on April 26, 2004.

Dated: April 26, 2004

Peter I. Bernstein

3. Lawrence, et al., "Differential Hepatocyte Toxicity of Recombinant Apo2L/TRAIL Versions", Nature Medicine, Vol. 7, No. 4, pp. 383-385, (2001);
4. A. Ashkenazi, et al., "Death Receptors: Signaling and Modulation", SCIENCE, Vol. 281, pp. 1305-1308, (1998);
5. R.M. Pitti, et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family", The Journal of Biological Chemistry, Vol. 271, No. 22, pp. 12687-12690, (1996);
6. H. Walczak, et al., "Tumoricidal Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand *In Vivo*", Nature Medicine, Vol. 5, No. 2, pp. 157-163, (1999); and
7. S. Nagata, "Steering Anti-Cancer Drugs Away from the TRAIL", Nature Medicine, Vol. 6, No. 5, pp. 502-503, (2000).

Applicants are submitting copies of the above-cited references.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required.

Respectfully submitted,



Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
PIB:ng

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE				Atty. Docket No. (Optional)		Application Number	
INFORMATION DISCLOSURE CITATION				15526 (PC23188A)		10/696,935	
<i>(Use several sheets if necessary)</i>							
				Applicant(s) Sing Rong, et al. Filing Date October 30, 2003			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
1.	S.R. Wiley, et al., "Identification and Characterization of a New Member of the TNF Family that Induces Apoptosis", <u>Immunity</u> , Vol. 3, pp. 673-682, (1995)						
2.	M. Jo, et al., "Apoptosis Induced in Normal Human Hepatocytes by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand", <u>Nature Medicine</u> , Vol. 6, No. 5, pp. 564-567, (2000)						
3.	Lawrence, et al., "Differential Hepatocyte Toxicity of Recombinant Apo2L/TRAIL Versions", <u>Nature Medicine</u> , Vol. 7, No. 4, pp. 383-385, (2001)						
4.	Lawrence, et al., "Differential Hepatocyte Toxicity of Recombinant Apo2L/TRAIL Versions", <u>Nature Medicine</u> , Vol. 7, No. 4, pp. 383-385, (2001)						
5.	R.M. Pitti, et al., "Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family", <u>The Journal of Biological Chemistry</u> , Vol. 271, No. 22, pp. 12687-12690, (1996)						
6.	H. Walczak, et al., "Tumoricidal Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand In Vivo", <u>Nature Medicine</u> , Vol. 5, No. 2, pp. 157-163, (1999)						
7.	S. Nagata, "Steering Anti-Cancer Drugs Away from the TRAIL", <u>Nature Medicine</u> , Vol. 6, No. 5, pp. 502-503, (2000)						
EXAMINER				DATE CONSIDERED			
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							